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Summary-The content and release of acetylcholine (ACh) from cat brain and ACh content 
of rat brain was measured using the frog rectus and leech muscle bioassays before and after 
physostigmine 100 rg/kg i.v. or i.p. The drug elevates steady state levels of brain ACh of awake 
animals especially in the neocortex, caudate nucleus and hippocampus but much less so in the 
lateral geniculate and superior colliculus. Physostigmine was shown to produce neocortical 
release of ACh through a subcortical mechanism in brainstem transected cats and to decrease 
ACh neocortical content in pentobarbital anesthetized cats and rats. The neocortical release 
of ACh seems to be mediated primarily through a subcortical brain mechanism which is 
activated by physostigmine. It is postulated that the ascending reticular formation is involved. 
Local application of scopolamine (I pg/ml) into the collecting cup did not antagonize the 
effects of 100 pg/kg of physostigmine iv. as much as 1 mg/kg of scopolamine i.v. On the other 
hand, 2 mg/kg of mecamylamine given i.v. not only did not antagonize physostigmine-induced 
neocortical release of ACh, but seemed to enhance it. The results indicate a complex action of 
physostigmine on the cholinergic system of the brain. 
It is well known that physostigmine increases total brain acetylcholine (ACh) content 
(PAZZAGLI and PEPEU, 1964; ROSECRANS, DREN and DOMINO, 1968; MALPICA, JURUPE and 
CAMPOS, 1970). However, the per cent increase in regional brain ACh varies markedly 
(FISCHER, WESTERMANN and OELSSNER, 1969; MEGAZZINI, BERNARDI and BALLOT’& 1965). 
As might be expected on the basis of its well known anticholinesterase properties, 
physostigmine increases “free” brain ACh (BEANI et uf., 1969; CROSSLAND and SLATER, 
1968). A functional role for this increase in “free” ACh is suggested by the observation that 
physostigmine produces low voltage, desynchronized EEG activity (BRADLEY and ELKES, 
1953 ; LONGO and SILVESTRINI, 1957; YAMAMOTO and DOMINO, 1967). Under certain conditions 
physostigmine induces rapid eye movement (REM) sleep (CARRUYO and DOMINO, 1970; 
DOMINO, YAMAMOTO and DREN, 1968; KARCZMAR, LONGO and SCOTTI DE CAROLIS, 1970). 
Although there is not a 1 : 1 relation between EEG activation, ACh content and release, 
under most circumstances the correlation is quite high. During EEG activation the content 
of ACh is reduced and its cerebral release increased, with the reverse situation during EEG 
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synchronization (TOBIAS, LIPTON and LEPINAT, 1946; RICHTER and CROSSLAND, 1949; 
PEPEU and MANTEGAZZINI, 1964; MACINTOSH and OBORIN, 1953 ; MITCHELL, 1963 ; 
BARTOLINI and PEPEU, 1967; CELESIA and JASPER, 1966). During REM sleep cortical ACh 
release is as great as during wakefulness; in contrast, ACh release is reduced during non-rapid 
eye movement (NREM) sleep (JASPER and TESSIER, 1971). The effects induced by physostig- 
mine, a&opine and scopolamine are the best known exceptions to the relation of EEG-ACh 
content and release. 
Physostigmine appears to have actions other than its well known anticholinesterase 
effects. It releases ACh from isolated guinea pig atria (BARTOLINI and OCELLO, 1965) and 
rat brain slices (BERTELS-MEEUWS and POLAR, 1968) and has possible direct neuronal 
agonisticeffects (BRADLEY, DHAWAN and WOLSTENCROFT, 1966). Physostigmine has biphasic 
effects on pentobarbital sleeping time depending upon dose (BARNES and MEYERS, 1964; 
DAVIS, KING and BABBINI, 1971; KALYANPUR and PRASAD, 1967). 
Inasmuch as the cholinergic agonist and antagonist, physostigmine and scopolamine, 
are the best known exceptions to the relation between EEG and cortical ACh content and 
release, we decided to clarify their mechanisms of action. It was decided that it would be of 
value to compare in the cat the effects of physostigmine on regional brain ACh content with 
its effects on cortical release with and without pentobarbital. The cat was chosen because of 
its brain size. In addition, the effects of physostigmine and pentobarbital were studied on rat 




Fifteen mongrel adult cats of both sexes were used. All surgery was performed under 
halothane-air anaesthesia. Suitable cannulae were inserted in the trachea, vein, artery for 
adequate ventilation, i.v. injections and recording arterial BP. The animal’s head was placed 
in a stereotaxic apparatus. In order to avoid the complications of anaesthesia during the 
experiment, a brainstem transection was made by means of a stereotaxically oriented spatula. 
Most of the cats were transected at a midpontine pretrigeminal level but some were 
transected at a collicular prepontine level. The atlanto-occipital membrane was opened to 
allow free drainage of the cerebrospinal fluid. Shortly following transection, the skull was 
opened over a large part of the frontoparietal area. The cats were allowed to recover from the 
halothane anaesthesia for 3 hr. During this interval they resumed spontaneous respiration. 
Body temperature was maintained with a heating pad as close to 37°C as possible, as 
monitored by a rectal probe. Cats in which either brain hemorrhage or edema occurred were 
discarded. Blood pressure was recorded from the femoral artery by means of a Statham 
pressure transducer and recorded on a polygraph. 
The collecting cups were constructed according to MITCHELL (1963). After opening the 
dura, a perspex cylinder covering 0.76 cm2 of the cortex was lowered onto the sensorimotor 
and its posterior association area with the aid of an adjustable electrode carrier. The 
cylinder was filled with 0.7 ml of a Ringer’s medium containing (concentration in g/l.) 
NaCI 9.0; KC1 0.42; CaC1,0.24; NaHCO, 0.5; glucose 1 .O and physostigmine sulphate 0-l. 
Every 10 min the solution was aspirated from the collecting cup and bioassayed immediately 
for ACh using the dorsal muscle of the leech according to the, method of MURNAGHAN 
(1958). The muscle was suspended in a 2 ml bath. The upper end of the muscle was connected 
to a small mirror which reflected a beam of light onto a graduated scale approximately 5 ft 
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away on the wall allowing a 200 fold magnification. The samples collected from the cups 
were diluted with distilled water (I .O volume diluted to 1.4 volumes) to achieve isotonicity 
with the leech Ringer solution. The samples were then compared with standard solutions of 
ACh HCI containing the same concentration of physostigmine. In order to assure that 
maximal cholinesterase inhibition had occurred in the area of the cortex beneath the cup, 
samples from the first four IO-min intervals were not assayed. Evidence that the substance 
released into the cup was either ACh or some very similar choline ester has been given 
previously (MITCHELL, 1963; SZERB, 1963; BARTOLINI and PEPEU, 1967). The electrical 
activity of the cerebral cortex was recorded by means of screw electrodes inserted into the 
skull and a silver ball electrode placed inside the collecting cup. In all experiments the drugs 
were injected through a polyethylene cannula inserted into the femoral vein. Following 
termination of the experiment, the brainstem transection was determined macroscopically. 
ACh content 
(A) Fifteen adult cats of both sexes were divided into three groups. The first group 
received saline, the second 40 mg/kg of pentobarbital together with 100 pg/kg of physo- 
stigmine and the third group 40 mg/kg of pentobarbital alone, all i.p. Within a few minutes 
the cats receiving pentobarbital were comatose. Those also receiving physostigmine showed 
cholinergic symptoms such as diarrhea. Fifteen minutes after injection, the cats were 
sacrificed by decapitation utilizing a large pneumatic guillotine. The skull was quickly 
sawn midsagitally and the brain removed and placed on ice. From each brain 10 samples 
were isolated. These included the right and left lateral geniculate, superior colliculus, caudate 
nucleus, hippocampus and primary visual cortex. The samples were weighed on a Roller- 
Smith torsion balance and homogenized in a tube with a chilled mixture of 0.2% acetic 
acid in 95 y0 ethyl alcohol. A maximum time of 7 min elapsed between decapitation and the 
onset of homogenization. ACh was extracted according to the method of STONE (1955) and 
CROSSLAND (1961) and bioassayed the same day, as described previously. That the extracted 
substance was ACh or a similar choline ester was established by the following: (1) the muscle 
did not respond to the extract after treatment with d-tubocurarine hydrochloride 
(3 x 10~~ g/ml), (2) the substance was stable in an acid medium, (3) boiling in an alkaline 
medium abolished its ability to elicit a muscle response. 
(B) Fifty four Holtzman male albino rats weighing about 250 g were divided into three 
groups. Each group received the same treatment as described previously for the three groups 
of cats. Fifteen minutes after injection the rats were decapitated by guillotine. In one series, 
the entire brain (excluding cerebellum, olfactory lobes and pituitary) and in the other a 
large portion of the cerebral cortices of both hemispheres were removed quickly and total 
ACh was extracted by the method of STONE (1955) and CROSSLAND (1961). The ACh-like 
activity of the extracts was bioassayed on the isolated frog (Runa pipiens) rectus abdominis 
muscle preparation. As suggested by FELDBERG (1945), ACh standards were prepared in 
alkali-inactivated extracts to allow for the presence of sensitizing factors in the brain tissue. 
RESULTS 
EfSects of physostigmine and pentobarbital on acetylcholine content 
As shown in Table 1, pentobarbital in a dose of 40 mg/kg i.p. produced a highly 
significant increase of ACh in the visual cortex, caudate nucleus and hippocampus of cats. 
When pentobarbital was administered together with 100 yg/kg of physostigmine, no further 
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Table 1. Effects of physostigmine and pentobarbital on acetylcholine content of some cerebral areas of the cat 
Treatment 
Lateral Superior Visual Caudate 
geniculate colliculus cortex nucleus Hippocampus 
Saline 
Pentobarbital 
40 mg/kg i.p. 
Pentobarbital 
40 mg/kg i.p. 
Physostigmine 
100 pg/kg i.p. 
(6) (6) (5) (6) (7) 
8.711.3 7.8hO.9 1.2&O.] 4.2*0.3 2.6*0.3 
(5) (8) (6) (8) (8) 
9.7kO.9 7.8*1.1 2.910.4 6.2f0.3 3.250.2 
(13) (13) (12) (13) (6) 
9.8*1.0 8.111.4 1.8kO.2 6.110.5 3.410.6 
The number of experiments are given in the parentheses. Data expressed as mean 5S.E. in pg/g wet weight. 
Cats were sacrificed 15 min after i.p. injection. 
statistically significant ACh increase occurred in the caudate and hippocampus. What is 
more surprising, in the visual cortex a significant ACh decrease was obtained in comparison 
to pentobarbital alone. In addition, neither pentobarbital alone nor pentobarbital plus 
physostigmine changed the ACh levels of late,ral geniculate body and superior colliculus. 
Because of these unexpected findings, some of the experiments were repeated in rats. In male 
Holtzman rats the cortical ACh was also significantly lower after pentobarbital with physo- 
stigmine than after pentobarbital alone (Table 2). However, the cortical ACh content after 
pentobarbital plus physostigmine was greater than after saline. In contrast, the ACh content 
of whole rat brain was almost the same with pentobarbital plus physostigmine as with 
pentobarbital alone. Both treated groups had a brain ACh content higher than the saline 
control group, as expected. The results on whole rat brain are therefore similar to those on cat 
caudate nucleus and hippocampus. 
Table 2. Effects of physostigmine and pentobarbital on acetylcholine content of the neocortex and whole 







Pentobarbital40 mg/kg i.p. 
Pentobarbital40 mg/kg i.p. 
Physostigmine 100 pg/kg i.p. 








4.7Ito.3 12 4.8f0.2 
Rats were sacrificed 15 min after the i.p. injection. TheP values for group comparison t-tests are given between 
various groups as indicated. The data are expressed as the mean &S.E. in rg/g wet weight. 
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Effect of physostigmine on cortical ACh release 
When lOOpg/kg ofphysostigmine was injected i.v. in brainstem transected cats an obvious 
mydriasis occurred, irrespective of the electrocortical activity. An obvious slight EEG 



















Fig. 1. Effect of physostigmine on cortical acetylcholine release as a function of basal output. 
The data are expressed in the form of three different superimposed bar graphs as shown. The per 
cent release varies with the basal level. Note with small basal outputs the per cent release is 
greater than with high basal output levels. However, in all cases physostigmine in a dose of 
100 pg/kg i.v. increased the release of ACh. This effect was maximal approximately 30 min after 
administration. It should be noted that in this and all subsequent experiments physostigmine 
was also present in the collecting cup in a concentration of 1 x 1O-4 g/ml. 
experiments on different cats are illustrated. The three animals had markedly different basal 
ACh release levels and were selected to show the ability of physostigmine to increase cortical 
ACh output. It is clear, however, that the effect of physostigmine is inversely proportional to 
the basal release level. The mean per cent increase of ACh output due to physostigmine was 
59 % in 4 experiments (Table 3). 
EfSect of IocaIly applied scopolamine on physostigmine evoked ACh release 
Physostigmine retained its ability to release ACh even after scopolamine HBr 
(1 x 1O-6 g/ml) was placed in the collecting cup (Fig. 2). The high basal release level caused 
by scopolamine is consistent with the well known stimulating effect of anticholinergic drugs 
on the ACh output. Local cortical application of scopolamine did not change the EEG 
pattern. The mean per cent increase of ACh release due to physostigmine injection after 
locally applied scopolamine was 65 % in 3 experiments (Table 3). 
Effect of intravenous scopolamine pretreatment on physostigmine evoked ACh release 
As expected, scopolamine HBr in a dose of 1 mg/kg i.v. markedly increased the basal 
cortical ACh release. Physostigmine in a dose of 100 pg/kg i.v. was administered 40 min 
after scopolamine injection when the evoked ACh release was maximal. After iv. scopolamine 





Fig. 2. Lack of effect of.locally applied scopolamine on physostigmine evoked acetylcholine 
release from the cat cerebral cortex. Local application of scopolamine in a concentration of 
1 pg/ml resulted in a high basal level of release of ACh from the cerebral cortex. However, this 
did not prevent the enhanced release of ACh following 100 pg/kg i.v. physostigmine. 
Table 3. Effect of scopolamine and mecamylamine on physostigmine evoked cortical 
acetylcholine release of brainstem transected cats 
Pretreatment 
Acetylcholine output 
(ng/cm2 per 10 min) 
Maximum after 
Before physostigmine 





5.5 8.2 + 49% 
4.8 9.9 +106% 
23.1 33.7 + 42% 









1 mg/kg i.v. 
Mean 
Mecamylamine HCI 
2 mg/kg i.v. 
Mean 
59.7 87.0 + 46% 
39.9 70.1 + 76% 
42.9 74.9 + 15% 
47.5 ii? + 65% 
73.8 81.9 + 11% 
44.5 57.8 + 29% 
50.5 56.4 i- 12% 
24.4 40.4 + 65% -__ 
48.3 59.1 + 29% 
18.8 37.9 +lol% 
14.0 26.1 + 86% 
16.4 32.0 + 93% 
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pretreatment the physostigmine effect was markedly reduced. The effects are illustrated in 
Figure 3 of a bar graph of one typical experiment. The mean per cent increase of ACh release 
due to physostigmine after scopolamine pretreatment was 29 % in 4 experiments (Table 3). 
Physostigmine given i.v. did not produce : m y obvious change in the scopolamine-induced 
















Scopblomme HBr Physbstigmine 
Img / kg i.v. 100 pg/kg i.v. 
Fig. 3. Antagonistic effect of iv. scopolamine on physostigmine-evoked acetylcholine release 
from the cat cerebral cortex. Scopolamine in a dose of 1 mg/kg i.v. caused an increase in ACh 
release. However, physostigmine administration after scopolamine caused only a slight increase 
in ACh release, indicating that scopolamine partially antagonized the effects of physostigmine. 



















Fig. 4. Failure of mecamylamine to block physostigmine-evoked acetylcholine release from 
the cat cerebral cortex. Mecamylamine did not block physostigmine-induced release of ACh. 
In fact, on a percentage basis, the release of ACh induced by physostigmine was somewhat 
greater than would be expected from normal basal release levels. Mecamylamine was given in 
dose of 2 mg/kg and physostigmine in a dose of 100 rg/kg i.v. at the times noted. 
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Ef/^ect of mecamylamine pretreatment on physostigmine evoked ACh release 
Mecamylamine in a dose of 2 mg/kg i.v. not only did not antagonize the physostigmine 
effect but it seemed to potentiate it. Moreover, mecamylamine itself slightly increased the 
basal release of ACh. These effects are illustrated in Figure 4 which depicts an experiment in 
which mecamylamine was injected 30 min before physostigmine. The EEG tracing was not 
significantly changed after iv. mecamylamine. Physostigmine still produced EEG activation 
in those animals that had a synchronized EEG. The mean per cent increase in cortical release 
of ACh due to physostigmine after mecamylamine pretreatment was 93 % (Table 3). 
DISCUSSION 
There are two major criticisms to research of this type. The first relates to the fact that 
dissections of cats’ brains were done on ice and that up to 7 min were required between 
dissection and denaturation of brain enzymes. One would expect obvious differences in 
regional brain temperature, depending upon contact with the ice and therefore different 
rates of synthesis and degradation of free and bound ACh. Thus, the values of regional ACh 
are not a measure of true ACh content in vivo. The same criticism would apply to the rat 
brain, but the total time from decapitation to protein denaturation would be much less. 
Since the order of dissection was exactly the same between the control and drug-treated series, 
drug differences from control would be relative, but still valid. We feel such an experimental 
approach, while far from ideal, is still acceptable. Secondly, there is a maximal rate of ACh 
release possible from the neocortex. Calculations based on the percent increase in ACh 
release following physostigmine, with and without prior treatment with scopolamine, can be 
misleading. However, when scopolamine was applied locally to the cortex the mean rate of 
ACh release was 47.5 ng/cm2 per 10 min. This was not the maximal rate of ACh release since 
physostigmine given i.v. increased ACh release up to 77.3 ng/cm2 per 10 min or a 65% 
increase. When scopolamine was given i.v. the mean ACh release was 48.3 ng/cm2/10 min and 
after physostigmine this was increased to 59.1 ng/cm2 per 10 min or only a 29 % increase. 
In both the rat and cat pentobarbital anaesthesia elevated cerebral cortical levels of ACh. 
In these barbiturate-anaesthetized animals physostigmine in moderate doses reduced 
significantly the cortical ACh levels compared to pentobarbital alone. Compared to saline 
the cortical levels of ACh were still significantly elevated. As is true of ACh itself, physostig- 
mine has biphasic dose-dependent actions on the autonomic and CNS activity as reflected 
in its effects on respiration and other subcortical functions. The effect is characterized 
by stimulation or facilitation in low concentrations, succeeded by inhibition or paralysis at 
higher concentrations (PATON and PERRY, 1953; KOELLE, 1970). Since the ACh content of the 
neocortex is lower during EEG activation than synchronization (PEPEU and MANTEGAZZINI, 
1964), our observation of a decrease in cortical ACh content of pentobarbital anaesthetized 
animals induced by physostigmine is in good agreement with its arousal properties in low to 
moderate doses (BRADLEY and ELKES, 1953 ; LONGO and SILVESTRINI, 1957 ; YAMAMOTO and 
DOMINO, 1967). All previous data showing that physostigmine increases brain ACh content 
were obtained in awake animals already having a low brain ACh content. Under such 
experimental conditions it is impossible, considering physostigmine-induced cholinesterase 
inhibition, to reveal a decreasing effect of physostigmine on brain ACh content. 
The finding that physostigmine reduces slightly the elevated cortical levels of ACh in 
pentobarbital anaesthetized animals is, of course, in complete agrement with the data of 
others that physostigmine alone elevated brain ACh above control levels (BEANI et al., 1969; 
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CROSSLAND and SLATER, 1968; FISCHER et al., 1969; MALPICA et al., 1970; MECAZZINI et al., 
1965; ROSECRANS et al., 1968). 
The ability of physostigmine to reduce cortical ACh content pfobably is due to its ACh 
releasing property. Physostigmine, 100 pg/kg i.v., in fact always increased cortical ACh 
output either in EEG activated or synchronized cats. The ACh-induced release, however, was 
proportionally greater in cats previously having EEG slow waves. This observation together 
with the fact that physostigmine was present in the collecting cup throughout the experiment, 
allows one to suggest that the increased ACh release following physostigmine was con- 
comitant to cortical EEG activation. CELESIA and JASPER (1966) and BARTOLINI and PEPEU 
(1967) have demonstrated that an activated EEG pattern is associated with a high release of 
ACh from the neocortex and a synchronized EEG pattern with a low ACh release. 
BARTOLINI and OCELLO (1965) showed that physostigmine increased within the first few 
minutes of contact the basal release of ACh from isolated guinea pig’s atria beating in vitro. 
This effect seemed to be unrelated to the physostigmine-induced cholinesterase inhibition. 
BERTELS-MEEUWS and POLAK (1968) subsequently showed that physostigmine decreases ACh 
content and increases ACh release from rat brain cortex slices incubated in a high potassium 
medium in vitro and pretreated with the cholinesterase inhibitor Soman. Since physostigmine 
in our experiments was already present in very high concentrations (1 x IO-* g/ml of 
physostigmine sulphate) in the collecting cup before its i.v. injection, it is possible to rule out 
a direct effect of physostigmine on the cerebral cortex. It is also possible to rule out that the 
enhanced ACh release is due to a greater inhibition of cortical cholinesterase for it is probably 
already maximally inhibited. It is important to stress that we have found that i.v. scopolamine 
in contrast to local cortically applied scopolamine blocked or markedly reduced the 
physostigmine-evoked ACh release. It appears, therefore, that physostigmine acts on 
subcortical structures because only systemically administered scopolamine blocked its 
effect and because physostigmine was already locally present. If the iv. physostigmine 
effect was the result of a greater inhibition of cortical cholinesterases it would be very difficult 
to explain either the i.v. scopolamine blocking action or the cortical ACh content decrease in 
pentobarbital treated cats and rats. The simplest explanation of the phenomenon observed 
is that i.v. physostigmine increases the ACh available at subcortical receptors, especially in 
the reticular formation or its ascending elements either through a direct ACh releasing 
action or through cholinesterase inhibition. The ACh evoked stimulation of the ascending 
reticular formation could be the cause either of EEG arousal, cortical ACh release and 
depletion. Several experiments support this hypothesis. These include: (A) Microelectro- 
phoretic studies have shown that reticular neurons are excited by ACh and by physostigmine 
(BRADLEY et al., 1966; SALMOIRAGHI and STEINER, 1963). Moreover, atropine specifically 
blocks the actions of ACh, particularly the excitatory effects upon the response of ACh- 
sensitive reticular neurons (BRADLEY et al., 1966). (B) SHUTE and LEWIS (1963, 1967) have 
studied the histochemical distribution of acetylcholinesterase in the rat brain. They have 
described cholinergic pathways from the ventral tegmental area and substantia nigra to the 
neocortex. (C) Evoked cortical potentials due to electrical stimulation of the midline and 
medial regions of the midbrain tegmentum (reticulocortical potentials) are totally blocked by 
i.v. administration of muscarinic cholinergic antagonists, but not by their cortical 
application. Furthermore, the i.v. administration of anticholinesterase agents markedly 
potentiates the amplitude of reticulocortical potentials (ILYUTCHENOK and ZINEVICH, 1970). 
(D) An EEG activation response is elicited either by direct electrical stimulation of the 
mesencephalic reticular formation or by cholinergic agonists such as ACh, physostigmine, 
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arecoline, pilocarpine and oxotremorine (LONGO and SILVESTRINI, 1957; EVERETT, 1964; 
YAMAMOTO and DOMINO, 1967). Furthermore, muscarinic cholinergic antagonists like 
atropine, but not nicotinic cholinergic antagonists like mecamylamine, block EEG 
desynchronization produced by muscarinic agonists including physostigmine (CELESIA and 
JASPER, 1966; EVERETT, 1964; YAMAMOTO and DOMINO, 1967). Similarly, our experiments 
show that systemically administered scopolamine, but not mecamylamine, markedly reduces 
the physostigmine-evoked ACh release from the neocortex. 
CELFSIA and JASPER (1966) have shown that local cortical application of neostigmine to 
sleeping animals causes local desynchronized activation followed by local epileptiform 
discharge without changing the rateof ACh liberation. Again, this data indirectly suggests the 
necessity for the anticholinesterase agents to stimulate subcortical structures in order to 
obtain both EEG activation and the increase of cortical ACh release. 
MEGAZZINI et ul. (1965) have shown that choline acetylase activity is significantly 
greater in the neocortex and cerebellar vermis of guinea-pigs treated for one week with 
physostigmine, 100 pg/kg i.p. Our results help to explain Megazzini’s data by showing that 
the increased choline acetylase activity is probably induced because physostigmine increases 
cortical ACh release. Finally, YAMAMOTO and DOMINO (1967) found that i.v. mecamylamine 
not only did not decrease physostigmine-evoked EEG activation but significantly increased 
its duration. Similarly, our data show that mecamylamine potentiated physostigmine 
evoked ACh release from the neocortex. 
In conclusion, the present results have clarified the apparent contradiction between the 
different actions of physostigmine to alter brain ACh content as well as causing EEG 
activation. Furthermore, a subcortical mechanism seems to be involved. 
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